Biomea Fusion, Inc.

Biomea Fusion, Inc. hit a potentially damaging bump in the road on 6 June, revealing that the US Food and Drug Administration placed BMF-219, testing a novel mechanism of action for type 1 and type 2

Alzheimer’s disease is top of mind due to the millions of people in need of effective treatments and the rapid rise in the AD population globally – and because the first disease-modifying therapy has

Two drug developers went public – Rain Therapeutics Inc. and Impel NeuroPharma, Inc. – late on 22 April, closing out a week that ended with the Nasdaq Biotechnology Index (NBI) in positive territo

Surrozen Inc. is raising $212m in 2021 as it prepares to enter the clinic in 2022, going public through a merger with the special purpose acquisition corporation (SPAC) Consonance-HFW Acquisition Cor